🇺🇸 FDA
Patent

US 11951100

Formulations of RBP4 inhibitors and methods of use

granted A61KA61K31/437A61K31/4545

Quick answer

US patent 11951100 (Formulations of RBP4 inhibitors and methods of use) held by Belite Bio, Inc expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Belite Bio, Inc
Grant date
Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/437, A61K31/4545, A61K9/10, A61K9/146